Lamivudina + Zidovudina Farmoz

Zidovudine and Lamivudine, the active ingredient in Lamivudina + Zidovudina Farmoz, is a nucleoside reverse transcriptase inhibitor presented as an oral tablet for oral use. It treats human immunodeficiency virus (HIV) infection in adults and children.

GNH USA supplies Lamivudina + Zidovudina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudina + Zidovudina is an antiretroviral medication used in the management of HIV infection and related therapeutic pathways.

- HIV‑1 infection: reduces viral load and helps restore immune function. - HIV‑2 infection: suppresses viral replication and improves clinical outcomes. - Prevention of mother‑to‑child transmission: lowers the risk of vertical HIV transmission when administered to pregnant women.

Adverse reactions may occur with Lamivudina + Zidovudina and are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: generalised tiredness. - Anemia: reduction in red blood cell count. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Severe lactic acidosis: metabolic disturbance requiring urgent care. - Hepatic steatosis: fatty liver disease with potential liver dysfunction. - Severe neutropenia: marked decrease in neutrophils increasing infection risk. - Hypersensitivity reactions: rash, fever, or organ involvement. - Pancreatitis: inflammation of the pancreas with abdominal pain.

Before initiating therapy with Lamivudina + Zidovudina, clinicians should consider several safety measures.

- Monitor blood counts: regular CBC to detect anemia or neutropenia. - Assess liver function: periodic LFTs to identify hepatic toxicity. - Evaluate renal function: adjust use in impaired kidneys. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Use caution in pregnancy: weigh benefits against potential risks. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lamivudina + Zidovudina may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Didanosine: increased risk of peripheral neuropathy and pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Alcohol: potentiates hepatotoxic effects.

Moderate Interactions (Monitor Closely): - Rifampin: reduces plasma concentrations of both agents. - Antacids containing aluminium or magnesium: may impair absorption. - Protease inhibitors (e.g., ritonavir): alter pharmacokinetics requiring dose adjustment.